Sun Pharma’s arm receives USFDA’s approval for Generic Lenalidomide Capsules

10 Feb 2023 Evaluate

Sun Pharmaceutical Industries’ one of wholly owned subsidiaries has received final approval from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic lenalidomide Capsules, 5mg, 10mg, 15mg, 25mg and tentative approval for 2.5mg, 20mg. The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product.

In June 2021, Sun Pharma had entered into a settlement with Celgene Corporation (Celgene) to resolve the patent litigation regarding Sun Pharma’s generic lenalidomide capsules. Pursuant to the terms of this settlement, Celgene granted Sun Pharma a license to Celgene’s patents required to manufacture and sell certain limited quantity of generic lenalidomide capsules in the US beginning sometime after March 2022. In addition, the license allows Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning January 31, 2026.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1785.00 -41.10 (-2.25%)
10-Jan-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1785.00
Dr. Reddys Lab 1354.20
Cipla 1475.25
Lupin 2185.50
Zydus Lifesciences 1003.00
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.